DaShenLin Pharmaceutical Group Co (SHSE:603233) Long-Term Debt: ¥501 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603233 DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
96 GF Score
Price ¥18.17
GF Value ¥18.79
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is DaShenLin Pharmaceutical Group Co Long-Term Debt?

DaShenLin Pharmaceutical Group Co SHSE:603233 +0.17% 96 Long-Term Debt is ¥501 Mil as of Mar. 2026. GuruFocus rates SHSE:603233 with a GF Score™ of 96/100 and a GF Value™ of ¥18.79 (Fairly Valued). The stock has 4 warning signs investors should review.

DaShenLin Pharmaceutical Group Co's Long-Term Debt for the quarter that ended in Mar. 2026 was ¥501 Mil.

DaShenLin Pharmaceutical Group Co's quarterly Long-Term Debt declined from Sep. 2025 (¥1,919 Mil) to Dec. 2025 (¥463 Mil) but then increased from Dec. 2025 (¥463 Mil) to Mar. 2026 (¥501 Mil).

DaShenLin Pharmaceutical Group Co's annual Long-Term Debt increased from Dec. 2023 (¥1,638 Mil) to Dec. 2024 (¥1,846 Mil) but then declined from Dec. 2024 (¥1,846 Mil) to Dec. 2025 (¥463 Mil).

DaShenLin Pharmaceutical Group Co  (SHSE:603233) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

DaShenLin Pharmaceutical Group Co Long-Term Debt Related Terms

DaShenLin Pharmaceutical Group Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for DaShenLin Pharmaceutical Group Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DaShenLin Pharmaceutical Group Co Long-Term Debt Chart

DaShenLin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,252.15 1,461.44 1,637.68 1,845.91 463.03

DaShenLin Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,903.87 1,901.92 1,919.01 463.03 500.88
SHSE:603233
96GF Score
DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ¥501 Mil mean?
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a Long-Term Debt of ¥501 Mil as of Mar. 2026.
Is DaShenLin Pharmaceutical Group Co's Long-Term Debt too high?
DaShenLin Pharmaceutical Group Co's current Long-Term Debt is ¥501 Mil. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's Long-Term Debt compare to competitors?
DaShenLin Pharmaceutical Group Co's Long-Term Debt of ¥501 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Healthcare Providers & Services company?
A good Long-Term Debt depends on the Healthcare Providers & Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. DaShenLin Pharmaceutical Group Co's current Long-Term Debt is ¥501 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.79, compared to a current price of ¥18.17 — trading 3.3% below its estimated fair value. The current Long-Term Debt is ¥501 Mil. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current Long-Term Debt is ¥501 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?

Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥18.17 is trading 3.3% below its estimated GF Value™ of ¥18.79. GuruFocus considers DaShenLin Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:603233:

  • Long-Term Debt: ¥501 Mil
  • GF Value™: ¥18.79 vs. price of ¥18.17 (3.3% below fair value)
  • GF Score™: 96/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DaShenLin Pharmaceutical Group Co Business Description

Address No. 410-1, Longxi Avenue, Liwan District, Guangdong Province, Guangzhou, CHN, 510000
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
96GF Score

Get the complete analysis for SHSE:603233

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥18.17
Price
¥18.79
GF Value